We present the first clinical proof-of-concept that targeting BRD4-NUT with a BET inhibitor results in impressive and rapid antitumor activity in NMC. It offers strong potential for future clinical application in this rare patient population as either single agent or in combination.
INTRODUCTION
The role of BRD4 in cancer and the potential of bromodomain and extra-terminal (BET) inhibitors to therapeutically target it, was first identified in NUT midline carcinoma (NMC) (1, 2) , a disease harboring BRD4-NUT, the only known oncogene form of BRD4. NMC is a recently described poorly differentiated squamous cell carcinoma (SCC), typically affecting head and neck and thoracic structures. It is observed equally in males and females, and over all ages (range 0-78 years) (3). While considered rare, this tumor is likely underdiagnosed due to the need for a specific (100%) and sensitive (87%) immunohistochemistry (IHC) test for nuclear NUT expression (4) .
Nonetheless NMC should be considered in the differential diagnosis of any aggressive poorly differentiated carcinoma in the absence of a viral or other known etiology. With a median survival of only 6.7 months, NMC is a very aggressive solid tumor, with most patients having locally advanced or metastatic disease at diagnosis (5) . While response to chemotherapy occurs, patients invariably relapse rapidly and are refractory to subsequent treatments (5) .
NMC is defined genetically by chromosomal rearrangements involving the NUT gene on chromosome 15q14. In approximately two-thirds of cases, NUT is fused to BET gene BRD4 on chromosome 19p13.1, creating an in-frame BRD4-NUT oncogene driven by the BRD4 promoter, or less commonly to other genes including BRD3 and NSD3 (1, (5) (6) (7) . BRD4 is a member of the BET protein family, including BRD2, BRD3 and BRDT. BET proteins are components of transcription factor complexes and are thought to be determinants of epigenetic memory (8) . The BRD-NUT oncoprotein is considered a major pathogenetic driver of cellular transformation (6) . Consistent with its oncogenic function to block differentiation, siRNA knockdown of BRD4-NUT in NMC cells results in differentiation and growth arrest (6) , providing a strong rationale for targeting these proteins.
BRD4-NUT function is dependent upon the acetyl-histone-binding of the BRD4 bromodomains (6, 9, 10) . BET inhibitors are acetyl-histone mimetic compounds that target BRD4 by competitively inhibiting its binding to chromatin. Indeed, treatment with the paradigm BET inhibitor, JQ1 (an OTX015/MK-8628 analog), depletes BRD4-NUT from chromatin and induces rapid growth arrest (2, 10) . BRD4 has been shown to play a role in many cancers (11, 12) , and at least six clinical trials using BET inhibitors have been initiated (NCT01713582, NCT02259114, NCT02296476, NCT01587703, NCT01987362, NCT02158858).
OTX015/MK-8628, a novel synthetic small molecule targeting BRD2, BRD3 and BRD4, inhibits proliferation in a wide range of hematologic malignancies and solid tumor cell lines (13, 14) . In vivo, OTX015/MK-8628 inhibited tumor growth in the Ty82 NMC model harboring a BRD4-NUT fusion (15) . We report here on the first NMC patients treated with OTX015/MK-8628 on a compassionate basis.
RESULTS

Patient 1
A 39-year-old female was diagnosed in February 2012 with grade 3 invasive ductal carcinoma of the left breast, positive for hormone receptors and HER2/neu. She received neoadjuvant epirubicin and cyclophosphamide followed by paclitaxel and herceptin. Herceptin and hormone therapy were administered after surgery/radiotherapy. In June 2013, a CT scan showed a 2x3 cm nodule on the left lower lobe of the lung, with increased uptake on an FDG-PET scan (SUV max , 8.8). A percutaneous core biopsy was initially interpreted as adenosquamous carcinoma. In August 2013 a left lobectomy with mediastinal lymph node dissection revealed a poorly differentiated carcinoma, with extensive necrosis and angio-invasion, morphologically different from the previous breast carcinoma. IHC revealed nuclear NUT protein expression in all tumor cells that were negative for hormone receptors and Her2/neu (Fig. 1A) . Fluorescence in situ hybridization (FISH) was positive for BRD4-NUT fusion confirming the NMC diagnosis (Fig. 1B) . Molecular profiling confirmed the BRD4-NUT fusion and revealed an activating NOTCH mutation (c.4793G>A (p.R1598H), exon 26) previously described in adenoid cystic carcinoma (16) . The tumor lacked additional known oncogenic driving mutations, rearrangements, or copy number variation (Supplementary Tables   S1-2 
Patient 2
A 22-year-old male, was diagnosed in May 2014 with a poorly differentiated carcinoma of the nasopharynx with extensive bone metastases. This diagnosis was subsequently revised to NMC (Fig. 3A) , confirmed by the presence of a BRD4-NUT fusion by FISH (data not shown). Molecular profiling showed no additional oncogenic mutations, copy number variation, or rearrangements other than the BRD4-NUT (Supplementary Tables S1-2). He received two cycles of docetaxel, cisplatin and 5-fluorouracil. Despite an initial brief clinical response, his disease progressed rapidly after the second cycle. Two cycles of cisplatin and etoposide were administered and a decrease in volume on facial lesions was observed during the week that followed cisplatin/etoposide, administered as a 21-day cycle, with a new increase in tumor growth starting around day 15.
Finally, a CT scan after the second cycle of cisplatin/etoposide confirmed disease progression.
The patient was referred in August 2014 with severe dorsolumbar pain due to extensive bone metastases despite opioids and NSAIDs. Laboratory analyses revealed increased LDH (2.3x ULN) and alkaline phosphatase (3.3x ULN). Physical examination showed a bulky tumor involving the left maxillary and mandibular region extending to the ipsilateral cervical lymph nodes. OTX015/MK-8628 was initiated and a dramatic clinical response was achieved with almost complete disappearance of the bulky facial tumor by physical examination after 8 days (Fig. 3B) . Pain also improved rapidly, and after an initial increase on day 8, LDH levels were normal by day 15. At the end of cycle 2, a PET-CT showed partial response ( Fig. 3C-D) .
Treatment was complicated by nausea, dysgueusia, anorexia, hyperglycemia (all grade 2) and thrombocytopenia (grade 3). OTX015/MK-8628 was interrupted during cycle 2 for non-hematologic toxicity and the dose was reduced to 60 mg QD from cycle 3. Clinical evidence of local tumor progression was apparent at the end of cycle 3 (Fig 4A) . A tumor biopsy from a local tumor relapse at the mandibular region confirmed NMC progression, with a greater degree of squamous differentiation (Fig. 4B) . Analysis of a post-tumor biopsy confirmed decreased NUT expression in areas of differentiation, whereas NUT expression was unchanged in undifferentiated cells (Fig.   4C) . The differentiation seen here may be evidence of the on-target pro-differentiative effects of BRD4-NUT inhibition (2) . The molecular profile was identical to that of the pretreatment biopsy (Supplementary Tables S1-2) . The patient received a fourth cycle ending in October 2014, at which time he deteriorated rapidly and died the following month, seven months following his initial diagnosis.
Patient 3
A 66-year-old female was diagnosed with locally advanced small cell lung carcinoma in May 2014 and received four cycles of carboplatin/etoposide. After review, diagnosis of NMC was established based on IHC and FISH. Molecular profiling was not possible due to insufficient tissue.
OTX015/MK-8628 was initiated in September 2014. The patient had grade 2 dyspnea due to a bulky tumor (8x6.5 cm) on the right lung invading the superior lobe bronchus, pulmonary artery, and posterior wall of the superior vena cava, along with increased LDH (1.6x ULN). Treatment was interrupted for 5 days after the first two weeks due to nausea and fatigue (grade 2) with worsening dyspnea. Nausea and fatigue improved to grade 1 while dyspnea returned to baseline levels. A thorax CT after cycle 1 showed stable disease. Treatment was resumed at 60 mg QD. Stable disease was seen after cycle 2, along with a limited SUV max reduction (7 vs 10 at baseline). Cycle 3 was marked by grade 2 nausea and fatigue and treatment was discontinued at the end of this cycle (September 2014) when a PET-CT showed progression. Radiotherapy (45 Gy) to the lung achieved a partial response which was later followed by disease progression during administration 
NUT+ NMC cells is dependent upon NSD3-NUT interacting with BRD4 (7). NSD3-NUT is thought
to form a BRD4-NUT-like complex that is tethered to chromatin via its association with BRD4. In support of this, NSD3-NUT+ NMC cells differentiate and arrest growth in the presence of JQ1 (7).
Thus there is mechanistic rationale for use of BET inhibitors in patients with BRD3-NUT+ or NSD3-NUT+ NMC.
The role of wild-type BRD4 in other cancers is related to its pro-transcriptional function to facilitate transcriptional elongation of coding and enhancer RNAs (18) . In the non-NMC cancer context, it is a key component of cell-type specific super-enhancers that drive expression of genes promoting growth and/or block differentiation, including, in many but not all cases, c-MYC (19) . Despite these differences in BRD4-NUT and BRD4 enrichment within chromatin, in vitro and in vivo findings demonstrate exquisite sensitivity of BRD4 super-enhancer-dependent growth to BET inhibitors in a wide range of non-NMC cancers (11, 19) . By contrast, regular enhancers are relatively resistant to BET inhibitors (19) . Thus, BET inhibition is also a valid targeting approach in a broad range of non-NMC cancers. Fig. S1 ). Alternatively, it was recently shown that triple negative breast cancer can overcome BET inhibition through BRD4 phosphorylation, allowing it to remain associated with chromatin through interaction with MED1 (24) . In our NMC patients, BRD4-NUT may be bypassed by similar or squamous-cell specific pathways to activate MYC expression. These findings consequently support the need for additive (or synergistic) combination treatment strategies in 
METHODS
Patients and Treatment
Four patients with advanced NMC failing previous therapy were treated with OTX015/MK-8628 on a single-patient compassionate-use basis at the Oncology Institute of Southern Switzerland.
Treatment was given in accordance with the Declaration of Helsinki under investigator responsibility. All patients gave written informed consent prior to treatment. OTX015/MK-8628 (supplied by Oncoethix SA) was administered orally at 80 mg once daily (QD) with 3-week cycles, a safe and pharmacodynamically active dose based on an ongoing first-in-human Phase I study in hematologic malignancies (20, 21) . Dosing was interrupted and/or reduced according to toxicity.
Fluorescence In Situ Hybridization (FISH)
BRD4 and NUT dual color split-apart and bring-together FISH on formalin-fixed, paraffinembedded sections was performed as described (7), using NUT 3' telomeric probes, RP11-1H8 and RP11-64o3 (digoxigenin labeled, green), and BRD4 5' centromeric probes, RP11-207i16 and RP11-3055m5 (biotin labeled, red). 200 nuclei were counted in four different areas of each tumor.
Eighty percent positive interpretable nuclei were defined as positive for a rearrangement.
Immunohistochemistry
IHC for NUT was performed on 5-micron-thick, formalin-fixed, paraffin-embedded sections. Slides underwent heat-induced epitope retrieval in citrate buffer and were incubated with primary rabbit monoclonal anti-NUT (clone C52B1,1:50) (Cell Signaling Technology, Danvers, MA) and visualized using Bond Polymer Refine Detection (Leica Microsystems, Buffalo Grove, IL). 
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